Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma 3Solid Tumors 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Carcinoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 52Cytarabine 49fludarabine phosphate 38fludarabine 32Filgrastim 30Etoposide 23Rituximab 19Azacitidine 17Whole-Body Irradiation 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Decitabine 13Clofarabine 13venetoclax 12Melphalan 12Antilymphocyte Serum 12Mycophenolic Acid 11Methotrexate 11Radiotherapy 10Mitoxantrone 10Daunorubicin 10Busulfan 10sargramostim 9aldesleukin 9Vincristine 9Sirolimus 9Topotecan 8Idarubicin 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia × darinaparsin × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡